Guggenheim initiated coverage on Pharvaris N.V. with a new price target
$PHVS
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $32.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $32.00 | Buy | Guggenheim |
| 4/29/2025 | $28.00 | Overweight | Cantor Fitzgerald |
| 9/25/2023 | $27.00 | Outperform | Wedbush |
| 8/15/2023 | $10.00 → $34.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/5/2022 | $16.00 | Buy | Bryan Garnier |
| 9/13/2022 | $34.00 → $18.00 | Mkt Outperform | JMP Securities |
| 8/23/2022 | $40.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
| 8/22/2022 | $26.00 → $13.00 | Neutral → Underperform | BofA Securities |